IDH2 and acute myeloid leukemia: Since Enasidenib received approval for AML indications for recurrent/refractory IDH2 mutations in 2017, there have been many clinical trials investigating the efficacy of mutant IDH2 inhibitors (mainly Enasidenib) in different AML subtypes and solid tumors (Table 3).